MedPharm Ltd. has opened a new £0.5m GMP facility in Guildford. The investment adds a new microbiology lab, cleanroom suites, a dedicated ICH stability testing area and quality control and performance testing labs to support Phase I and II clinical manufacture. The facility also allows for the manufacture of highly potent compounds to OEB 4 level with a manufacturing batch scale of up to 50kg and primary packaging, labeling and randomization services.
Dr. Andrew Muddle, MedPharm’s chief executive officer, said, "The opening of the new site is a huge milestone for our business. We can now offer a true one-stop shop for formulation development, all provided in house. We have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements. In particular, the bespoke clinical trials supplies production facility, regulated by state-of-the-art monitoring systems, will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms. These include liquids, semi-solid gels, creams and ointments, as well as inhaled products, sprays and transdermal patches to name but a few.”